# Bridging the Gap: Scientific Advice's Role in Health Technology Success

**Introduction to HTA and Scientific Advice**

- Definition of HTA
- The role of scientific advice in HTA
- Importance of HTA in healthcare decision-making

2. **Why Seek Scientific Advice in HTA?**
   - Enhancing product development strategies
   - Anticipating health economic and clinical outcomes
   - Navigating regulatory and reimbursement challenges
3. **How to Obtain and Implement HTA Scientific Advice**
   - Step-by-step approach to engaging with HTA bodies
   - Preparing for HTA scientific advice (briefing books, evidence generation plans)
   - Informal versus formal scientific advice mechanisms
4. **Who Should Seek Scientific Advice?**
   - Pharmaceutical and biotech companies
   - Medical device and technology firms
   - Academia and research institutions
5. **When to Seek Scientific Advice**
   - Early development stages
   - Pre and post-market authorization
   - Timing considerations for maximum impact
6. **What Constitutes Effective Scientific Advice?**
   - Components of high-quality scientific advice
   - Real-world evidence (RWE) generation and utilization
   - Clinical trial design and surrogate endpoints
7. **The Use of Scientific Advice for Health Economics**
   - NICE scientific advice for economic modeling
   - Cost-effectiveness assessments
   - Budget impact analyses
8. **Scientific Advice for Clinical Trials**
   - Trial comparator relevance
   - Eligible populations and biomarker subpopulations
   - Endpoint selection and trial design considerations
9. **Expanding the Scope: RWE and Beyond**

- The growing importance of RWE in HTA
- Challenges in developing high-value RWE
- Utilization of innovative study designs

10. **Joint Scientific Advice with Regulatory Bodies**
    - EMA joint scientific advice process
    - Benefits of multi-agency scientific advice
    - Case studies of joint scientific advice outcomes
11. **Future Directions: EUnetHTA and Joint Scientific Consultations**
    - Overview of EUnetHTA's role in harmonizing HTA across Europe
    - Upcoming joint scientific consultation processes
    - Strategies for successful engagement
12. **Conclusion and Best Practices**
    - Summary of key takeaways
    - Recommendations for optimizing the scientific advice process
    - Long-term strategies for HTA engagement
13. **Appendices**
    - Glossary of terms
    - List of HTA agencies and their scientific advice offerings
    - Templates and checklists for scientific advice preparation
14. **References and Further Reading**

## Introduction to HTA and Scientific Advice

In healthcare, Health Technology Assessment (HTA) stands as a pivotal process for evaluating the implications and value of healthcare interventions. From novel pharmaceuticals to advanced medical devices and diagnostics, HTA offers a comprehensive assessment that integrates clinical efficacy, safety, cost-effectiveness, and the societal impact of new technologies. At its core, HTA informs policy decisions, guiding the allocation of often scarce resources to optimize patient outcomes and societal benefit.

The complexity and rigor of HTA necessitate a strategic approach from the early stages of healthcare product development. This is where scientific advice becomes instrumental. Scientific advice is a structured framework

within which manufacturers and developers can seek guidance from HTA bodies and regulatory agencies. This proactive engagement facilitates a mutual understanding of evidence requirements and assessment criteria, ensuring that new health technologies align with the expectations and standards of those who evaluate them.

But why is scientific advice gaining such traction in the health technology sphere? The answer lies in its ability to bridge the gap between innovation and access. As healthcare systems grapple with the fast pace of medical advancement, they face the challenge of integrating breakthrough therapies that promise clinical improvement but come with significant costs. Scientific advice serves as a conduit for aligning the objectives of technology developers with the sustainable implementation of these technologies within healthcare systems.

The exchange of scientific advice is a dialogue—a collaborative effort that aims to clarify the evidence needed to demonstrate the value of a new health technology. This dialogue is not just about meeting the minimum requirements for market entry but about understanding the nuances of evidence that will resonate with payers, clinicians, and ultimately, the patients. By engaging in this process, companies can refine their clinical development plans, optimize their economic models, and anticipate potential hurdles in the regulatory and HTA process.

In the quest for a favorable HTA recommendation, timing is paramount. Engaging with HTA bodies early in the development process allows for iterative feedback and evidence generation that is both targeted and efficient. It provides a roadmap for generating data that not only supports regulatory approval but also addresses the multifaceted questions posed by HTA agencies. This includes, but is not limited to, the comparative efficacy of the intervention, its long-term benefits and risks, and its impact on the quality of life of patients.

Moreover, scientific advice is not a one-size-fits-all solution. It is customized to the unique attributes of each health technology and the specific context of its intended use. It can range from advice on the PICO (population, intervention, comparator, outcmes) and clinical trial design, to guidance on economic modeling and the use of real-world evidence (RWE). As such, the

process of seeking and implementing scientific advice is as diverse as the technologies it seeks to assess.

The evolving nature of HTA demands adaptability and foresight from technology developers. This eBook is crafted to shed light on the nuances of seeking and utilizing scientific advice in HTA. Through the ensuing chapters, we will explore the strategic role of scientific advice, its execution, and the entities involved, alongside its timing and content. We will delve into its application in health economics, its integration with clinical trials, and the role of RWE. Furthermore, we will talk about the collaborative synergy of joint scientific advice with regulatory bodies and the prospective landscape shaped by entities like EUnetHTA.

Looking at the complexities of HTA is an important challenge, but with the strategic application of scientific advice, technology developers can anticipate the needs of HTA bodies and pave the way for successful technology adoption. As we embark on this exploration, we aim to equip you with the general knowledge, mindset and tools to harness scientific advice effectively, ensuring that your healthcare innovations achieve their full potential in improving patient care and health system value.



## Chapter 1 - Why Seek Scientific Advice in HTA?


The pursuit of scientific advice in the context of HTA is not merely a procedural step but a strategic imperative for health technology innovators. This chapter looks into the 'why'—unravelling the compelling reasons that drive companies to seek scientific advice from HTA bodies.

At the forefront, scientific advice serves as a navigational beacon in the turbulent waters of healthcare innovation. The development and introduction of a new health technology are fraught with uncertainties. Scientific advice provides a platform for engaging with HTA agencies to clarify these uncertainties, align expectations, and establish a clear and evidence-based value proposition for the technology.

One of the primary motivators for seeking scientific advice is the complex and often stringent regulatory environment. Companies must navigate a maze of regulatory requirements, and early engagement with HTA bodies can offer critical insights into the evidentiary standards needed for a successful assessment. It is an opportunity to understand the perspectives of payers and regulatory authorities, ensuring that the clinical and economic evidence generated will satisfy their criteria for effectiveness and efficiency.

Moreover, the advice received can significantly influence the design and conduct of clinical trials. Selecting the appropriate comparators, endpoints, and patient populations based on HTA recommendations can lead to more relevant and robust data. This can expedite the journey towards market access by demonstrating clear clinical benefits and cost-effectiveness, which are essential for pricing and reimbursement decisions.

In health economics, scientific advice is equally vital. Economic evaluations are central to HTA processes, and early advice can guide the development of economic models that accurately reflect the value of the technology. This is crucial in the era of precision medicine, where therapies may be highly effective but also highly priced. Companies must justify the investment in their innovations by presenting compelling economic arguments that resonate with the fiscal priorities of healthcare systems.

Another critical aspect is the ever-increasing importance of real-world evidence (RWE). As healthcare moves towards a more patient-centric approach, the ability to demonstrate the real-world impact of a technology becomes paramount. Scientific advice can help define the parameters for RWE studies, ensuring that the evidence collected post-market also contributes to the body of knowledge supporting the technology's value proposition.

The dynamic nature of healthcare technology demands adaptability. Scientific advice provides a proactive approach to keep abreast of changing HTA methodologies, evidentiary requirements, and healthcare priorities. It helps companies to anticipate and adapt to changes, rather than react to them, which can be the difference between success and obsolescence.

Furthermore, seeking scientific advice is a declaration of a company's commitment to transparency and collaboration. It demonstrates a willingness

to engage in open dialogue with HTA bodies and to refine their product development in line with expert feedback. This collaborative approach can build trust and credibility, which are intangible assets in the healthcare industry.

Lastly, the globalization of healthcare markets means that companies must consider the diverse requirements of HTA bodies across different regions. Scientific advice can facilitate an understanding of these varied landscapes, enabling companies to devise a globally coherent strategy that still respects local nuances.

In essence, scientific advice in HTA is an indispensable tool for aligning healthcare innovation with the demands of efficacy, safety, and economic viability. It empowers companies to make informed decisions, fosters collaborative relationships with regulatory and HTA agencies, and ultimately, guides the development of technologies that not only succeed in the market but also genuinely improve health outcomes.

## Chapter 2 - How to Obtain and Implement HTA Scientific Advice



Navigating the Health Technology Assessment (HTA) landscape requires a well-charted course, and obtaining scientific advice is the compass by which health technology innovators can steer their journey. This chapter outlines the procedural map for acquiring and integrating HTA scientific advice—a crucial step in the development and successful market entry of new health technologies.

The initial step in obtaining scientific advice involves identifying the appropriate HTA body or bodies relevant to the health technology in question. This selection is pivotal and is influenced by various factors, including the geographic market, the therapeutic area, and the specific requirements of the technology. Once identified, the process of engagement can begin.

The cornerstone of this engagement is the preparation of a briefing book—an exhaustive document that outlines the technology, its intended use, the available evidence, and specific questions for which the innovator seeks advice. This briefing book serves as the basis for all subsequent interactions with the HTA bodies and should be crafted with meticulous care, ensuring clarity and completeness.

Key to the briefing book's effectiveness is its alignment with global evidence plans and its adaptability to local market nuances. It should package clinical data in accordance with HTA guidelines and incorporate any global strategy while being sufficiently flexible to address market-specific needs and questions.

Following the briefing book submission, the actual dialogue with HTA bodies commences. This dialogue typically takes the form of face-to-face meetings, although increasingly virtual interactions are also common. These consultations are the medium through which the innovator can discuss, clarify, and refine their approach based on the scientific advice received. It is a collaborative process, and success hinges on the innovator's openness to feedback and their agility in responding to it.

Once the advice is received, the implementation phase begins. It is not enough to simply obtain advice; it must be operationalized within the technology's development plan. This may entail redesigning clinical trials to incorporate advised comparators and endpoints, revising economic models, or planning for additional data collection to address identified gaps.

The implementation of scientific advice is not a singular event but an iterative process. It may require ongoing dialogue with HTA bodies, especially as new data emerges or as the healthcare landscape evolves. As such, maintaining a relationship with HTA bodies throughout the product lifecycle is beneficial.

Scientific advice also can play a role in RWE. Post-market, the advice can guide the design of studies to collect RWE that supports the ongoing assessment of the technology's impact in real-world settings. This is increasingly important as HTA bodies and payers demand evidence beyond controlled clinical trial environments.

For companies operating in multiple jurisdictions, the complexity of implementation increases. It may involve balancing and synthesizing advice from various HTA bodies while navigating the intricacies of each market's healthcare system. The process, therefore, demands not only scientific and technical expertise but also strategic regulatory intelligence.

In summary, obtaining and implementing HTA scientific advice is a sophisticated and strategic endeavor. It requires careful planning, a thorough understanding of regulatory and HTA landscapes, and a proactive and responsive approach. This chapter has mapped the contours of this process, providing innovators with the insights necessary to harness the full potential of HTA scientific advice, ensuring their technologies can successfully navigate the path to market access and ultimately improve patient care.



## Chapter 3- Who Should Seek Scientific Advice?


Scientific advice within HTA is a valuable asset across a broad spectrum of stakeholders in the healthcare sector. This chapter identifies and discusses the various entities that stand to benefit from seeking scientific advice and the reasons why they should engage in this vital process.

**Pharmaceutical and Biotechnology Companies:** These are perhaps the most direct beneficiaries of HTA scientific advice. As developers of new drugs and biological treatments, pharmaceutical and biotech companies are at the forefront of innovation in healthcare. For them, scientific advice is an opportunity to align their development strategies with the evidentiary demands of HTA bodies. By engaging early, they can ensure that their clinical

trials are designed to generate the data needed to demonstrate both clinical effectiveness and cost-effectiveness, thus facilitating smoother market entry and reimbursement.

**Medical Device and Technology Firms:** The medical device sector covers a vast array of products, from simple tools to complex machinery. The companies that develop these technologies must demonstrate not only their safety and efficacy but also how they compare to existing standards of care. Scientific advice can guide these companies in conducting the appropriate comparative analyses and economic evaluations to meet the specific requirements set by HTA bodies for medical devices.

**Diagnostic and Digital Health Companies:** As healthcare becomes increasingly personalized, the role of diagnostics, including companion diagnostics, grows ever more critical. Similarly, digital health is revolutionizing the way healthcare is delivered, necessitating a new set of assessment criteria. Companies in these sectors should seek scientific advice to understand how their innovations can be assessed within the existing frameworks and what additional evidence might be required to demonstrate their value.

**Health Economics and Outcomes Research (HEOR) Professionals:** These individuals or groups specialize in evaluating the economic impact and clinical outcomes of healthcare interventions. Scientific advice can provide HEOR professionals with insights into the latest methodologies and expectations of HTA bodies, ensuring that their evaluations are robust, relevant, and aligned with current standards.

**Academic Institutions and Research Organizations:** Research in the healthcare sector is not confined to industry. Academic institutions and research organizations play a key role in advancing medical knowledge. When these entities are involved in the development or assessment of new health technologies, seeking scientific advice can help ensure that their research efforts are directed towards areas of significant impact and are designed to meet the rigorous standards of HTA assessments.

**Patient Advocacy Groups:** While not traditional seekers of scientific advice, patient advocacy groups have a vested interest in ensuring that new technologies meet the needs of the patients they represent. Engaging with

HTA bodies can provide these groups with a better understanding of the assessment process and enable them to advocate more effectively for the inclusion of patient perspectives in the evaluation of new health technologies.

**Regulatory Consultants and CROs:** Consultants and Contract Research Organizations (CROs) that assist companies in navigating the regulatory landscape should also be well-versed in the nuances of HTA scientific advice. Their role is to guide clients through the complexities of both regulatory approval and HTA assessment, and as such, their expertise in obtaining and interpreting scientific advice is crucial.

In conclusion, scientific advice is a multidimensional tool that serves a diverse array of stakeholders. Its purpose is to facilitate the development of health technologies that are not only innovative but also demonstrably effective and economically viable within the healthcare systems they aim to enter. Whether you are a pharmaceutical giant, a burgeoning biotech startup, a digital health pioneer, or an academic researcher, seeking scientific advice can provide a clearer path to delivering impactful health technologies to those who need them most.



## Chapter 4 - When to Seek Scientific Advice




Determining the optimal timing for seeking scientific advice in the HTA process is as crucial as the advice itself. This chapter examines the strategic points in a product's lifecycle when engaging with HTA bodies can be most beneficial and how this timing can influence the trajectory of healthcare innovation.

**Early Development Phases:** The axiom 'the earlier, the better' holds significant weight in the context of HTA scientific advice. Engaging with HTA bodies during the early phases of product development allows companies to incorporate critical input before major investments are made. Early advice can shape the foundational elements of clinical development, such as trial design

and PICO selection before pivotal phase 3 starts. It can ensure that the generated data will be relevant to both regulators and payers, thereby smoothing the path towards market access.

**Pre-Market Authorization:** As a health technology approaches the latter stages of clinical development, seeking scientific advice can help fine-tune the final stages of the evidence generation process. This is especially important for confirming that the data collected will meet the specific requirements of HTA bodies and payers. Addressing these requirements pre-emptively can prevent costly delays and revisions post-market authorization.

**During Regulatory Submission:** Concurrently with regulatory submission, seeking HTA scientific advice can provide insights into the market access landscape. It allows for the alignment of regulatory and reimbursement strategies, ensuring that submissions to regulatory bodies are complemented by robust economic and outcomes data that will satisfy HTA requirements.

**Post-Market Authorization:** Even after a technology has been granted market authorization, the HTA process continues to evaluate its performance and impact. At this stage, scientific advice can guide the development of post-marketing studies and helping in selecting the appropriate collection of real-world evidence. These efforts are critical for confirming the technology's value proposition and can inform pricing, reimbursement negotiations, and market expansion strategies.

**During Health Policy Shifts:** Healthcare is a dynamic field, and policy shifts can occur with the introduction of new legislation, changes in clinical guidelines, or shifts in health system priorities. Seeking scientific advice during these times can help companies understand and adapt to these changes, ensuring that their products remain relevant and continue to meet the evolving needs of the healthcare system.

**When Expanding to New Markets:** Entering new geographic markets can present a host of new HTA challenges. Scientific advice can be invaluable in understanding the specific requirements and preferences of HTA bodies in different regions. This understanding can guide the adaptation of clinical and economic evidence to meet local standards, facilitating smoother market entry and uptake.

**In Summary:** There is no one-size-fits-all answer to when a company should seek scientific advice in the HTA process. Instead, the decision should be guided by the product's development stage, the company's strategic goals, and the evolving landscape of the healthcare system. Timing the request for scientific advice strategically can maximize its impact, ensuring that health technologies are developed and assessed in a way that aligns with the expectations of HTA bodies, payers, clinicians, and patients. By integrating scientific advice at these critical junctures, companies can navigate the complex process of bringing innovative health technologies to market with greater confidence and success.

## Chapter 5 - What Constitutes Effective Scientific Advice?




This chapter looks into the key components that make scientific advice truly impactful for health technology developers and the broader healthcare ecosystem.

**Clear and Actionable Guidance:** The essence of effective scientific advice lies in its clarity and actionability. It should provide specific, detailed recommendations that can be directly applied to the development process. This includes guidance on clinical trial design, selection of appropriate PICO, and the types of economic analyses most relevant to HTA bodies. Clear advice allows developers to make informed decisions, reducing the risk of costly

missteps and ensuring that the generated evidence aligns with the expectations of payers and regulators.

**Alignment with Regulatory and HTA Expectations:** Effective scientific advice bridges the gap between innovation and regulatory (and HTA) compliance. It aligns the development of health technologies with the current standards and expectations of both regulatory and HTA bodies. This alignment is crucial, as it ensures that the evidence generated will support both market approval and positive HTA recommendations, facilitating smoother access to healthcare markets.

**Incorporation of Real-World Evidence (RWE):** The growing emphasis on RWE in healthcare decision-making has made its incorporation into scientific advice increasingly important. Effective advice should guide developers on how to design and implement studies that collect RWD to be transformed useful RWE, which complements clinical trial data. This includes recommendations on data sources, methodologies, and analytical techniques that are most likely to be accepted by HTA bodies and payers, enhancing the credibility and relevance of the evidence base.

**Flexibility and Adaptability:** The dynamic nature of healthcare innovation requires scientific advice to be flexible and adaptable. It should take into account the evolving landscape of medical research, regulatory standards, and healthcare priorities. Effective advice anticipates future trends and challenges, providing developers with the foresight needed to navigate the complexities of the healthcare sector.

**Stakeholder Engagement:** Involving a broad range of stakeholders, including patients, healthcare professionals, and payers, in the scientific advice process ensures that the guidance received is comprehensive and reflective of diverse perspectives. This engagement is critical for understanding the real-world implications of health technologies, ensuring that the advice not only supports regulatory approval and reimbursement but also addresses the needs and expectations of end-users.

**Transparency and Documentation:** Effective scientific advice is characterized by transparency in the decision-making process and thorough documentation of the advice provided. This includes clear rationales for the recommendations made, as well as an outline of any assumptions or

uncertainties considered. Such transparency builds trust among stakeholders and facilitates the implementation of the advice, as developers have a clear understanding of the basis for the guidance received.

**Collaborative Approach:** Finally, the process of obtaining and implementing scientific advice should be collaborative, involving ongoing dialogue between developers and HTA bodies. This collaborative approach allows for continuous feedback and adjustments, ensuring that the development process remains aligned with HTA requirements and expectations.

In summary, effective scientific advice is multifaceted, encompassing clear and actionable guidance, alignment with regulatory expectations, incorporation of RWE, flexibility, stakeholder engagement, transparency, and a collaborative approach. These components collectively ensure that health technology developers are equipped with the knowledge and insights needed to navigate the HTA landscape successfully, ultimately leading to the delivery of innovative, effective, and accessible healthcare solutions.

## Chapter 6 -The Use of Scientific Advice for Health Economics

In HTA, the integration of health economics is indispensable. This chapter explores how scientific advice is leveraged to navigate the complex domain of health economics, ensuring that health technologies not only meet clinical efficacy but also demonstrate economic value.

**Foundation of Health Economic Assessments:** The health technology from conception to market involves rigorous scrutiny of its clinical and economic impact. Scientific advice plays a pivotal role in guiding this journey, particularly in designing health economic assessments. These assessments evaluate the cost-effectiveness of technologies, comparing the additional cost of a new intervention to its additional benefits over existing standards.

Effective scientific advice ensures that these evaluations are built on solid, HTA-approved methodologies, aligning with the expectations of payers and decision-makers.

**Economic Modeling and Value Demonstration:** Health economics lies the challenge of demonstrating value. Scientific advice guides the development of economic models that accurately capture the full value of a technology. This includes direct healthcare costs, such as treatment and monitoring, as well as indirect costs, like productivity losses and quality of life improvements. By engaging with HTA bodies early, developers can ensure their models incorporate the appropriate comparators, perspectives, and time horizons, making a compelling case for the technology's adoption.

**Incorporating RWE:** The evolving landscape of HTA increasingly recognizes the importance of RWE in complementing clinical trial data. Scientific advice helps to identify opportunities for integrating RWE into economic evaluations, ensuring that these insights reflect the true impact of technologies in real-world settings. This may involve advice on the design of observational studies, the use of patient registries, or the analysis of healthcare databases, enhancing the robustness of the economic case presented.

**Addressing Uncertainty through Sensitivity Analyses:** Uncertainty is an inherent aspect of health economic evaluations. Scientific advice assists in identifying key areas of uncertainty and in designing appropriate sensitivity analyses. These analyses explore how changes in model inputs affect outcomes, providing a range of possible results. Through this process, developers can present a more nuanced understanding of their technology's value, addressing payers' concerns and facilitating informed decision-making.

**Engaging with Payers and Decision-makers:** Scientific advice also encompasses strategies for engaging with payers and other decision-makers. This may involve advice on presenting economic evidence, negotiating reimbursement schemes, or developing risk-sharing agreements. By understanding the priorities and concerns of these stakeholders, developers can tailor their value proposition, enhancing the likelihood of a favorable reception.

**Global Considerations in Health Economics:** The global nature of healthcare markets requires that economic evaluations be adaptable to different jurisdictions. Scientific advice can provide insights into the varied requirements of international HTA bodies and payers, guiding the customization of economic models to suit local contexts. This global perspective is crucial for technologies intended for widespread adoption, ensuring that economic evaluations are relevant and persuasive across diverse healthcare systems.

In conclusion, the use of scientific advice in health economics is a strategic imperative for the successful assessment and adoption of health technologies. It guides the development of rigorous, compelling economic evaluations that demonstrate value to payers, decision-makers, and ultimately, to the patients who stand to benefit. Through careful planning, robust modeling, and effective stakeholder engagement, health technology developers can navigate the economic dimensions of HTA, bringing innovative solutions to the market with confidence.



## Chapter 7 - Scientific Advice for Clinical Trials


Clinical trials are the backbone of evidence generation in healthcare, providing the critical data necessary for the assessment and approval of new medical interventions. Within HTA, the role of scientific advice in shaping these trials is paramount. This chapter looks into how scientific advice is employed to design and conduct clinical trials that meet the rigorous standards of HTA bodies, ensuring that new health technologies are effectively evaluated for their safety, efficacy, and value.

**Incorporation of Real-World Data (RWD) and Patient-Reported Outcomes (PROs):** Modern clinical trials increasingly incorporate RWD and PROs to provide a comprehensive view of an intervention's impact. Scientific

advice can offer insights into how these elements can be integrated into trials to meet HTA expectations. By capturing data on patient experiences, quality of life, and real-world effectiveness, trials can provide a more nuanced understanding of the intervention's value, enhancing its assessment by HTA bodies.

**Adaptive Trial Designs:** The complexity and dynamism of healthcare interventions call for innovative approaches to clinical trial design. Adaptive trials, which allow for modifications to the trial's parameters based on interim results, are gaining prominence. Scientific advice can assist in planning these adaptive aspects in a way that maintains the integrity and credibility of the trial in the eyes of HTA bodies, ensuring that modifications enhance, rather than compromise, the trial's relevance and robustness.

**Economic Evaluations Within Clinical Trials:** Integrating economic evaluations into clinical trials is a strategy that is increasingly advocated for. Through scientific advice, trial designers can understand how to embed health economic assessments into their studies from the outset. This proactive approach enables the collection of cost-effectiveness data alongside clinical outcomes, streamlining the HTA process and facilitating more informed decision-making regarding the intervention's reimbursement and use.

**Engagement with Stakeholders:** Effective clinical trials are those that consider the perspectives of all stakeholders, including patients, healthcare providers, payers, and regulatory bodies. Scientific advice can guide the engagement process, ensuring that the trial design addresses the needs and concerns of these groups. This stakeholder-centric approach not only enhances the relevance of the trial but also supports the broader acceptance and adoption of the intervention.

**Navigating Regulatory and Ethical Considerations:** Clinical trials must adhere to stringent regulatory and ethical standards. Scientific advice plays a crucial role in navigating these requirements, ensuring that trials are designed and conducted in compliance with regulatory guidelines and ethical principles. This guidance is essential for maintaining the integrity of the trial process and safeguarding participant welfare.

In conclusion, scientific advice is a critical tool in the design and execution of clinical trials for HTA. By aligning trial parameters with HTA requirements, incorporating comprehensive data elements, adopting innovative design strategies, and engaging with stakeholders, scientific advice ensures that clinical trials effectively support the evaluation and adoption of new healthcare interventions. Through this collaborative and strategic approach, scientific advice bridges the gap between clinical research and healthcare policy, contributing to the development of interventions that offer real value to patients and society.

## Chapter 8-Expanding the Scope: RWE and Beyond


The healthcare landscape is increasingly recognizing the value of Real-World Evidence (RWE) in complementing clinical trial data for HTA. RWE provides insights into how a health technology performs in the everyday clinical practice, offering a broader understanding of its efficacy, safety, and value. This chapter explores the expanding scope of scientific advice to include RWE, addressing its challenges, opportunities, and its pivotal role in HTA.

**The Growing Importance of RWE:** In an era where healthcare decisions are driven by evidence-based outcomes, RWE has emerged as a critical tool. It bridges the gap between controlled clinical trial environments and the variable conditions of real-world healthcare settings. Scientific advice plays a crucial role in guiding how RWE can be generated and utilized to support

HTA submissions. This involves advice on study design, data collection methodologies, and the integration of RWE with traditional clinical data to create a comprehensive evidence package.

**Challenges in Developing High-Value RWE:** While the potential of RWE is immense, its development and integration into the HTA process are not without challenges. These include ensuring the reliability and validity of real-world data sources, addressing biases inherent in observational studies, and meeting the methodological standards expected by HTA bodies. Scientific advice provides a roadmap for navigating these challenges, offering strategies for data validation, bias mitigation, and methodological rigor.

**Utilization of Innovative Study Designs:** The traditional boundaries of study designs are being expanded to accommodate the nuances of real-world data. Adaptive designs, pragmatic trials, and patient registries are becoming more prevalent, driven by the need for flexible and relevant evidence generation. Scientific advice is instrumental in selecting the appropriate design that aligns with HTA expectations, ensuring that the studies not only capture real-world outcomes but also adhere to high standards of evidence quality.

**RWE for Comparative Effectiveness and Safety Studies:** One of the key applications of RWE is in comparative effectiveness research (CER) and safety studies. These studies provide vital information on how a health technology compares to existing treatments and its safety profile in a broader patient population. Scientific advice guides the development of CER and safety studies that are methodologically sound and aligned with the specific interests of HTA bodies, enhancing the persuasiveness of the evidence presented.

**Stakeholder Engagement in RWE Generation:** Engaging with stakeholders, including patients, healthcare providers, and payers, is essential in the generation of RWE. Their insights can inform the focus of RWE studies, ensuring that the evidence generated is relevant and addresses the questions most pertinent to healthcare decision-makers. Scientific advice can facilitate this engagement process, identifying the stakeholders' evidence needs and integrating their perspectives into the study design.

**Impact of RWE on HTA and Policy Decisions:** The inclusion of RWE in HTA submissions has a profound impact on healthcare policy decisions. It offers a more nuanced view of a technology's performance, potentially influencing reimbursement strategies, clinical guideline development, and patient access policies. Scientific advice ensures that the RWE presented is compelling, accurately reflecting the technology's value in real-world settings.

In conclusion, the scope of scientific advice in HTA is expanding to encompass the generation and utilization of RWE. This shift reflects the evolving needs of the healthcare system for evidence that captures the complexity of real-world clinical practice. By addressing the challenges and harnessing the opportunities presented by RWE, scientific advice facilitates the development of robust, comprehensive evidence packages that support the assessment and adoption of health technologies, ultimately improving patient outcomes and healthcare value.



## Chapter 9-Joint Scientific Advice with Regulatory Bodies

In the evolving landscape of healthcare innovation, the collaboration between HTA bodies and regulatory agencies has become increasingly important. This chapter explores the concept of joint scientific advice, a process where developers engage simultaneously with HTA bodies and regulatory agencies to streamline the evaluation of new health technologies. This collaborative approach offers a harmonized perspective on clinical, regulatory, and economic requirements, enhancing the efficiency and effectiveness of health technology development and assessment.

**The Need for Joint Scientific Advice:** Health technology developers often face the challenge of meeting separate and sometimes divergent

requirements set by regulatory agencies and HTA bodies. Regulatory agencies focus on the safety and efficacy of a new intervention, while HTA bodies evaluate its comparative effectiveness and cost-effectiveness. Joint scientific advice seeks to bridge this gap by providing integrated guidance that addresses the needs of both entities, enabling developers to design studies that fulfill dual objectives.

**Benefits of Joint Scientific Advice:** The primary advantage of joint scientific advice is the potential for streamlined development and assessment processes. By obtaining harmonized guidance early in the development process, developers can avoid redundant or conflicting studies, reduce development timelines, and expedite access to market and reimbursement pathways. Additionally, this process promotes transparency and mutual understanding among stakeholders, fostering a more collaborative and efficient healthcare innovation ecosystem.

**The Process of Obtaining Joint Scientific Advice:** Engaging in joint scientific advice typically involves a structured interaction process. Developers submit a briefing package outlining the health technology, proposed development plan, and specific questions for both regulatory and HTA bodies. This is followed by a consultation meeting where feedback is provided, allowing developers to refine their plans based on integrated input. The process requires careful coordination and open communication, emphasizing the importance of a comprehensive and clear presentation of the technology and its development context.

**Challenges and Considerations:** Despite its benefits, the joint scientific advice process presents challenges, including logistical complexities and the need for alignment between different bodies with potentially varying priorities and methodologies. Success in this process requires a strategic approach, with careful planning and preparation, adaptability to feedback, and a commitment to ongoing dialogue throughout the technology's development.

**Looking Forward: The Future of Joint Scientific Advice:** As the healthcare landscape continues to evolve, the role of joint scientific advice in facilitating innovation and access to new technologies is expected to grow. Anticipation of future trends, such as the increasing emphasis on personalized medicine and digital health technologies, will require ongoing adaptation of the joint

scientific advice process. This includes considerations for new types of evidence, evolving regulatory and HTA criteria, and the integration of patient-centric outcomes.

In conclusion, joint scientific advice represents a critical mechanism for aligning the development of health technologies with the requirements of regulatory and HTA bodies. By fostering collaboration and integration of guidance, this process supports the efficient and effective delivery of innovative health technologies to patients, ultimately contributing to improved health outcomes and system value.



## Chapter 10- The Coming Joint Scientific Consultation of EUnetHTA

The European Network for Health Technology Assessment (EUnetHTA) plays a pivotal role in harmonizing HTA processes across Europe. With the healthcare landscape becoming increasingly complex and interconnected, the need for streamlined and efficient assessment processes has never been more critical. The introduction of joint scientific consultations by EUnetHTA represents a significant advancement in this endeavor, promising to enhance the collaboration between HTA bodies, and health technology developers. This chapter looks into the objectives, processes, and expected impact of the upcoming joint scientific consultations of EUnetHTA.

**Objectives of Joint Scientific Consultations:** The primary objective of EUnetHTA's joint scientific consultations is to offer a coordinated approach to HTA across member states. By facilitating early dialogue between health technology developers, EU HTA bodies, these consultations aim to streamline the evidence generation process, ensuring that it aligns with the needs and requirements of all stakeholders. This alignment is crucial for reducing redundancy, optimizing resource use, and accelerating the access of innovative technologies to the European market.

**The Process of Joint Scientific Consultations:** Joint scientific consultations involve a series of structured interactions between health technology developers and representatives from EUnetHTA, the different national HTA bodies. The process begins with the submission of a briefing package by the developer, outlining the health technology, its intended clinical use, and specific questions for feedback. This is followed by a consultation meeting where feedback is provided, allowing the developer to refine their development and evidence generation plans based on a harmonized set of recommendations.

**Challenges and Solutions:** Implementing joint scientific consultations across diverse healthcare systems presents several challenges, including variations in national HTA methodologies, priorities, and timelines. EUnetHTA addresses these challenges through rigorous procedural guidelines that ensure consistency and transparency in the consultation process. Additionally, efforts to foster mutual understanding and respect for different national practices are critical for the success of these consultations.

**Expected Impact on Health Technology Assessment:** The introduction of joint scientific consultations by EUnetHTA is expected to have a profound impact on the HTA landscape in Europe. By promoting early and coordinated dialogue, these consultations can significantly reduce the time and resources required for health technologies to be assessed and reach the market. This not only benefits developers by simplifying the assessment process but also ensures that patients have timely access to effective and innovative treatments.

Moreover, joint scientific consultations serve as a platform for sharing best practices and expertise among HTA bodies, enhancing the overall quality and efficiency of HTA. This collaborative approach is instrumental in addressing

the challenges of evaluating increasingly complex and personalized health technologies.

**Looking Forward:** As EUnetHTA continues to evolve, the role of joint scientific consultations in shaping the future of HTA in Europe cannot be overstated. These consultations represent a significant step towards a more integrated, efficient, and patient-centered HTA process. As they become more embedded in the European healthcare evaluation framework, their potential to facilitate the development and adoption of innovative health technologies will be fully realized, ultimately benefiting patients, healthcare providers, and health systems across Europe.

In conclusion, the joint scientific consultations of EUnetHTA mark a pivotal advancement in the harmonization of HTA practices. By fostering collaboration and streamlining the assessment process, they promise to accelerate the delivery of innovative health technologies to patients, while ensuring the sustainability and responsiveness of healthcare systems to emerging healthcare challenges.



## Conclusion and Best Practices


As we conclude our exploration into the realm of scientific advice in HTA, it's clear that this process represents a critical juncture in the development and assessment of health technologies. The journey through the intricacies of obtaining and implementing scientific advice, engaging with HTA bodies and regulatory agencies, and leveraging real-world evidence, among other aspects, underscores the multifaceted challenges and opportunities faced by health technology developers. This final chapter synthesizes key insights and outlines best practices to optimize the scientific advice process for the betterment of healthcare innovation and patient care.

### Synthesis of Key Insights:

- **Strategic Engagement:** Early and strategic engagement with HTA bodies and regulatory agencies through scientific advice is essential. It enables developers to align their evidence generation strategies with the expectations of these bodies, thereby facilitating smoother regulatory and market access pathways.
- **Integrated Evidence Planning:** A comprehensive and integrated approach to planning clinical and economic evidence is crucial. Scientific advice should guide not only clinical trial design but also the incorporation of health economics and real-world evidence to build a robust value proposition for the technology.
- **Stakeholder Collaboration:** Effective scientific advice processes involve collaboration with a broad range of stakeholders, including patients, healthcare providers, payers, and policymakers. Their insights can significantly enrich the evidence base and ensure that the technology meets real-world needs.
- **Adaptability and Flexibility:** The healthcare landscape is continually evolving, with new scientific, regulatory, and market access challenges. Developers must remain adaptable, using scientific advice to navigate these changes proactively.

**Best Practices for Optimizing the Scientific Advice Process:**

1. **Early Planning:** Initiate the process of seeking scientific advice early in the technology development cycle. This foresight can significantly impact the design and direction of development programs.
2. **Comprehensive Preparation:** Invest time in preparing detailed briefing packages for HTA and regulatory bodies. These documents should clearly articulate the technology's value proposition, development plan, and specific areas where advice is sought.
3. **Open Dialogue:** Foster an environment of open dialogue and transparency with HTA bodies and regulatory agencies. This approach facilitates constructive feedback and collaborative problem-solving.
4. **Leverage Multidisciplinary Expertise:** Engage multidisciplinary teams, including clinical, regulatory, health economics, and real-world evidence experts, to ensure that all aspects of the technology's value are addressed.

5. **Iterative Feedback Integration:** Treat scientific advice as an iterative process. Integrate feedback received into development plans promptly and seek follow-up advice as needed to address evolving challenges.
6. **Global Consideration:** For technologies intended for multiple markets, consider the international landscape of HTA and regulatory requirements. Seek joint scientific advice where possible to harmonize evidence generation efforts.
7. **Patient-Centricity:** Ensure that patient perspectives and outcomes are central to the evidence generation strategy. Scientific advice should be used to identify and incorporate relevant patient-reported outcomes and quality of life measures.

In embracing these best practices, developers can navigate the complexities of bringing innovative health technologies to market more effectively. The strategic utilization of scientific advice in HTA not only accelerates the development process but also ensures that new technologies meet the highest standards of clinical efficacy, safety, and economic value. Ultimately, the goal is to deliver solutions that significantly improve patient outcomes and enhance the quality of healthcare systems worldwide.



## Other references


1. PRMA Consulting offers an in-depth look at the principles and benefits of HTA early scientific advice, discussing the optimization of trial designs and the integration of cost-effectiveness considerations into HTA submissions.
2. The European Medicines Agency (EMA) provides guidance for applicants wishing to engage in parallel joint scientific consultation with regulators and HTA bodies, outlining the process and criteria for participation.
3. DIA Global Forum discusses the impact of Joint Scientific Consultations (JSC) and the Joint Clinical Assessments (JCA) on the regulatory and HTA collaboration in the EU, highlighting their role in facilitating systematic advice and creating efficiency in the system.
4. EUnetHTA describes the outcomes of the joint scientific advice procedure, including the receipt of a scientific advice letter from EMA and individual recommendations from participating HTA bodies.
5. ISPOR (International Society for Pharmacoeconomics and Outcomes Research) provides insights into early scientific advice from regulators and HTA, focusing on NICE's experience and its parallel advice with regulatory agencies.


*Prompted and Curated by Emmanuel Lacharme*
*Written by GPT-4*
*Illustrated by DALL-E*
*Diagrams by "AI Diagrams" Plugin*